Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
Patent 5246943 Issued on September 21, 1993. Estimated Expiration Date: 
May 19, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 19, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity 2-(2-aminobenzyl or 2-nitrobenzyl)-1,2,3,4-tetrahydroisoquinoline derivatives Bicyclic amine compound and a process for the preparation thereof Patent #: 5059608 InventorsApplicationNo. 885263 filed on 05/19/1992US Classes:514/307, Isoquinolines (including hydrogenated)514/310, Nitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bonding546/143, Nitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bonding546/144, Unsaturated ring attached directly to the six-membered hetero ring by nonionic bonding546/146, Having -C(=X)-, wherein X is chalcogen, attached directly or indirectly to the isoquinoline ring system by nonionic bonding546/147, The -C(=X)- is part of a -C(=X)X- group, wherein the X's are the same or diverse chalcogens546/149, Unsaturated carbocyclic ring attached indirectly to the six-membered hetero ring through an acyclic hydrocarbon chain546/150, Single bond between 3,4-positions560/40, Phenylalanines562/446, Di-oxy phenyl alanines568/442, Oxy containing568/638, Hydroxy containing (H of -OH may be replaced by a Group IA or IIA light metal)568/644PolyoxyExaminersPrimary: Ivy, C. WarrenAssistant: Turnipseed, James H. Attorney, Agent or FirmInternational ClassesA61K 031/47C07D 217/16 AbstractThis invention relates to novel substituted 1,2,3,4-tetrahydroisoquinolines which are useful in the treatment of vascular restenosis, various disorders of the central nervous system, in the regulation of female reproductive functions, in cognitive enhancement, in atherosclerosis and in treating excessive AVP secretory disorders. Novel intermediates useful in the preparation of the compounds are also disclosed. Methods of using the compounds and pharmaceutical compositions containing them are disclosed.Other References
Field of SearchUnsaturated carbocyclic ring attached indirectly to the six-membered hetero ring through an acyclic hydrocarbon chainNitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bonding Unsaturated ring attached directly to the six-membered hetero ring by nonionic bonding Having -C(=X)-, wherein X is chalcogen, attached directly or indirectly to the isoquinoline ring system by nonionic bonding The -C(=X)- is part of a -C(=X)X- group, wherein the X's are the same or diverse chalcogens Single bond between 3,4-positions Isoquinolines (including hydrogenated) Nitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bonding |
| ||||||||||||||
